PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
10-Apr-2025 NICE recommends BALVERSA®▼ (erdafitinib), the first and only treatment in the UK for metastatic or unresectable fibroblast growth factor receptor (FGFR3)-altered urothelial cancer (UC) for patients who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor Johnson & Johnson
10-Apr-2025 Ad-hoc: Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 2025 - for the first time more than EUR 10.7 million revenue in one month Cantourage Group SE
10-Apr-2025 Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 – for the first time more than EUR 10.7 million revenue in one month Cantourage Group SE
10-Apr-2025 Marinomed Biotech AG: Launch of new moisturizing Carragelose eye drops in Austria Marinomed Biotech AG
10-Apr-2025 Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update Relief Therapeutics Holding SA
10-Apr-2025 DocMorris accelerates Rx growth to 52 per cent and secures CHF 200 million capital increase through firm underwriting DocMorris AG
09-Apr-2025 PolyPeptide announces results of the annual General Meeting 2025 PolyPeptide Group
09-Apr-2025 AMRC welcomes Pratia as newest member, strengthening European representation AMRC
09-Apr-2025 YHEC Health Economic study suggests Steriwave technology could save UK hospitals c.£200 million savings (£2.38 saved for every £1 spent) from reducing surgical site infections in major surgeries Ondine Biomedical Inc
09-Apr-2025 Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments Immunic AG
09-Apr-2025 ValoTx Appoints Marcella Origgi from Johnson & Johnson Innovation as CEO Valo Therapeutics Oy
09-Apr-2025 Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Sanofi
09-Apr-2025 Beckman Coulter Life Sciences Launches Safer, Next-Generation Basophil Activation Test to Improve, Expedite Allergy Research Beckman Coulter Life Sciences
08-Apr-2025 Brainomix Advances Stroke Care with Landmark FDA Clearance Brainomix
08-Apr-2025 CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 CureVac
08-Apr-2025 CPI launches digitalisation blueprint to accelerate pharma towards net zero CPI
08-Apr-2025 ELRIG Appoints Dr Del Trezise as Chair ELRIG
08-Apr-2025 ADULT PATIENTS IN SCOTLAND WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH STAGE 1 AND 2 POLYNEUROPATHY CAN NOW ACCESS ASTRAZENCA’S WAINZUA™▼(EPLONTERSEN) AstraZeneca
08-Apr-2025 The Scottish Medicines Consortium (SMC) accepts Ipsen’s IQIRVO® (elafibranor) for use in NHS Scotland – the first new medicine in nearly a decade for primary biliary cholangitis (PBC), a rare liver disease Ipsen
08-Apr-2025 CAS and Cleveland Clinic collaborate to accelerate research through advanced AI and quantum computing CAS